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Fact Sheet 
Medicare Coverage Policies 
Myth: Blue Cross and Blue Shield of Florida implemented this policy. 
Fact: Blue Cross and Blue Shield of Florida performs its Medicare Part B business under 
contract with the federal government. Medicare contracts are performed on a cost 
reimbursement basis. Under contract, the Part B carrier is obligated to implement coverage 
policies that will protect Medicare and its 3.2 million beneficiaries across the state. 
Myth: Florida is the only state to have considered this type of skin lesion policy. 
Fact: While Florida was the first state to implement this type of policy, two other states 
(Mississippi and Rhode Island) have already implemented similar policies for the removal of 
skin lesions; and more are close behind. Florida has consistently been a leader among 
Medicare carriers in the country in many areas, including our claims payment system and our 
efforts to fight fraud, waste and abuse. 
Myth: Medicare doesn't pay for the removal of any skin lesions. 
Fact: Medicare does pay for the removal of benign or pre-malignant skin lesions when it is 
medically necessary for the patient to have them removed, based on medical research and 
scientific data from leading experts in the field. Since the policy was implemented in November 
1996, Medicare has paid more than go-percent of the claims submitted. 
Myth: Medicare is telling my physician how to practice medicine. 
Fact: Medicare reimburses physicians for services that are medically necessary and 
reasonable for the beneficiary. The skin lesion policy outlines when physicians will be 
reimbursed for the removal of skin lesions -- it does not outline how the physician should 
practice medicine. All medical decisions should be made between the physician and patient. 
We strongly encourage any patient who has a skin lesion to visit their physician right 
away -- Medicare will pay for the physician visit. 
Myth: Medicare doesn't care about the health of seniors. 
Fact: Medicare is very concerned about the quality of health care that Medicare beneficiaries 
receive in Florida. It is our duty to safeguard the Medicare system, and the federal government 
has entrusted us to do so. It is also our responsibility to make sure that we cover only services 
for beneficiaries that are medically necessary and reasonable. Medicare works across the 
state to educate beneficiaries on what Medicare covers and explain their Medicare benefits. 
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OUTPATIENT HOSPITAL TREATMENT Unlimited if medically 
Services for the diagnosis or treatment of an illness I necessary. 
or injury. 
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Medicare payment to 
hospital based on hospital 
costs. 
20% of billed amount 
(after $100 deductible).* 
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· starting with 4th pint). · additional pints (after 
$100 deductible). *** 
* Once you have had $100 of expense for covered services, the Part B deductible does not apply to any other covered services 
you receive for the rest of the year. 
** Federal law limits charges for physician services (see page 7). 
*** To the extent any of the three pints of blood are paid for or replaced under one part of Medicare during the calendar year they 
do not have to be paid for or replaced under the other part. 
DEFINITIONS OF SOME MEDICARE TERMS 
Actual Charge: The amount a physician or 
supplier actually bills for a particular medical 
service or supply. 
Approved Amount: The amount Medicare 
determines to be reasonable for a service that 
is covered under Part B of Medicare. It may be 
less than the actual charge. For many services, 
including physician services, the approved 
amount is taken from a fee schedule that as-
signs a dollar value to all Medicare-covered 
services that are paid under that fee schedule. 
Assignment: An arrangement whereby a phy-
sidan or medical supplier agrees to accept the 
Medicare-approved amount as full payment 
for services and supplies covered under Part B. 
Medicare usually pays 80% of the approved 
amount directly to the physician or supplier 
after the beneficiary meets the annual Part B 
deductible of $100. The beneficiary pays the 
other 20%. 
Benefit Period: A benefit periQd is a way of 
measuring a beneficiary's use of hospital and 
skilled nursing facility services covered by 
Medicare. A benefit period begins the day the 
beneficiary is hospitalized. It ends after the 
beneficiary has been out of the hospital or 
other facility that primarily provides skilled 
nursing or rehabilitation services for 60 days 
in a row. If the beneficiary is hospitalized after 
60 days, a new benefit period begins, most 
Medicare Part A benefits are renewed, and the 
beneficiary must pay a new inpatient hospital 
deductible. There is no limit as to the number 
of benefit periods a beneficiary can have. 
Coinsurance: The portion or percentage of 
the Medicar~approved amount that a benefi-
ciary is responsible for paying. 
Deductible: The amount of expense a benefi-
ciary must first incur before Medicare begins 
payment for covered services. 
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Excess Charge: The difference between the 
Medicare-approved amount for a service or 
supply and the actual charge, if the actual 
charge is more than the approved amount. 
Limiting Charge: The maximum amount a 
physician may charge a Medicare beneficiary 
for a covered physician service if the 
physician does not accept assignment of the 
Medicare claim. The limit is 15% above the 
fee schedule amount for non-partici-
pating physicians. Limiting charge informa-
tion appears on Medicare's Explanation of 
Medicare Benefits (EOMB) form. 
Medicare Carrier: An insurance organiza-
tion under contract to the federal government 
to process Medicare Part B claims from 
physicians and other suppliers. The names and 
addresses of the carriers and areas they serve 
are listed in the back of The Medicare Hand-
book, available from any Social Security Ad-
ministration office. 
Medicare Hospital Insurance: This is Part A 
of Medicare. It helps pay for medically neces-. 
sary inpatient care in a hospital, skilled nurs-
ing facility or psychiatric hospital, and for 
hospice and home health care. 
Medicare Medical Insurance: This is Part B 
of Medicare. This part helps pay for medically 
necessary physician services and many other 
medical services and supplies not covered 
by Part A. 
Participating Physician and Supplier: A 
physician or supplier who agrees to accept 
assignment on all Medicare claims. 
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Coverage for Benign or Premalignant Skin Lesion Removal 
i Background 
I 
Medicare B ofFlorida has developed a medical policy for these services as well as services for the removal of benign, either by shaving or excision (procedure codes 113 00 
through 11446); the destruction of benign facial or premalignant skin lesions in any location (p(ocedure codes 17000 through 17002) destruction by any method of 
complicated benign or premalignant lesions (procedure code 1701 0); destruction by any method benign or premalignant lesion on any area other than face ( 1710 l through 
17105); and the destruction by any method of flat warts or molluscum contagiosum and milia ( 17110). 
Covered Conditions and/or Diagnoses 
M-~dicare B will consider the destruction of a benign or premalignant skin 
• lesion medically necessary under the following circumstances: 
• • When the patient has multiple actinic keratoses and has self-administered 2% 
to 5% Fluorouracil topical cream for two to four weeks and the actinic 
keratoses have not responded to this treatment one to two months following 
treatment•, m: 
* It should be noted that the natural response to fluorouracil (Efudex) is 
erythema, usually followed by vesiculation, desquamation, erosion and 
reepithelialization. Therefore, during ~d immedicately following 
fluorouracil treatment these signs and symptoms would be considered 
part of the healing process and would not be considered as meeting the 
criteria for removal. There are contraindications for topical 
fluorouracil which include pregnancy, use on mucous membranes, use 
on mouth, and use around eyes or on nose. If after two months 
following treatment with fluorouracil, the actinic keratoses have not 
responded, they may be removed or destroyed. 
• When a patient presents with an actinic keratosis that has changed in size, has 
developed erythema, has thickened, has ulcerated, has eroded, has developed 
changes at the tumor margins, has become markedly hyperkeratotic, in which 
pain has developed and/or a cutaneous horn has developed; 
• When the patient presents with an actinic cheilitis (actinic keratosis of the 
lower lip) or an actinic keratosis on the upper lip; 
• When the patient presents with an actinic conjunctivae (actinic keratosis of the 
conjunctiva); 
• When the patient presents with an actinic keratosis on the nose, ear or eyelid; 
• When the patient presents with a actinic keratosis and has a history of one of 
the following: 
chronic immunosuppression such as that associated with organ transplan-
tation, particularly renal transplantation, and other disease processes such 
as Human Immunodeficiency Virus (HIV) or Acquired Immune Defi-
ciency Syndrome {AIDS) and/or chronic lymphocytic leukemia or 
lymphoma; 
- treatment of psoriasis with psolaren-ultraviolet A (PUV A) therapy; 






























CPT coding is based on the type of lesion (benign or premalignant), 
method of destruction or removal, and the number of lesions removed 
for any of the procedure codes within the following ranges: 113 00-
11313; 11400-11446; 17000-17002; or 17100-17110. 
If a lesion is destroyed or removed for any reason or for any cir-
cumstance other than ones listed in this article, the procedure is 
considered medically unnecessary and is, therefore, not reimbursur-
able by Medicare. 
When the patient is seen in the office for purposes of prescribing 
fluorouracil and providing instruc\.ion on how to use this medica-
tion, the appropriate level of Evaluation and Management service 
may be billed • 
Procedure code 17000 may only be billed once per day. Procedure 
code 17001 may be billed no more than two times in one day because 
the descriptor reads "2nd and 3rd lesion, each lesion". It is not appro-
priate to use the modifier-76 (repeat procedure) with these codes. 
Procedure codes 17100 through 17104 are to be billed in a similar 
manner. The first lesion should be billed utilizing procedure code 
17100. If a second lesion is removed, it should be billed utilizing proce-
dure code 17101. If three to fifteen lesions are removed on the same 
day as the first and second, procedure code 17102 may also be billed. 
Procedure code 17104 is used when fifteen or ~ore lesions are re-
moved. It is not appropriate to bill this code with 17100, 17101, or 
17102 m: to bill with the modifier -76. 
• 
Coverage for Benign or Premalignant Skin Lesion Removal (con't) 
Covered Conditions and/or Diagnoses (con't) 
- previous treatment of a biopsy-proven Squamous Cell Carcinoma (SCC). 
• When a patient presents with an arsenical keratosis (due to arsenic exposure); 
• When a patient presents with a keratosis and has a history of significant exposure to therapeutic 
or occupational radiation therapy (chronic radiation kertosis). 
• When a patient presents with a keratosis which arises from an old scar ( chronic cicatrix 
keratosis). 
If none of the aforementioned conditions exist, Medicare B of Florida would consider 
the removal of an actinic keratosis as medically unnecessary and, therefore, not reim-
bursable by Medicare. 
In addition, chemical peels of the face, even in the presence of actinic keratoses, are 
considered medically unnecessary in nature because the technique is used to improve the 
appearance of photodamaged skin~ and is, therefore, not reimbursable by Medicare. 
The total number ofservices billed utilizing procedure codes 17000, 17001, .and.17002 
which exceed the number that woul~ be considered medically necessary and rea~onable 
according to established parameters will be reviewed on a prepayment basis using the cri-
teria above and may be denied as not medically necessary or reasonable. 
Generally, the removal of benign lesions such as seborrheic keratoses, sebaceous cysts, and 
warts are done for cosmetic reasons, however, in mt instances it may be necessary to remove 
these types of lesions. Medicare B of Florida will consider the removal of these lesioris as 
medically necessary for any of the following reasons: 
: • the lesion is in an area such as the neck or waist and is constantly irritated and/or is located in 
an anatomical location of recurrent trauma and that such trauma has in fact occurred; 
• the lesion obstructs an orifice or clinically obstructs vision (this would include any lesion); 
· • the patient presents with condylomata acuminta (venereal warts) and/or is immunosuppressed; 
and/or, 
I • plantar warts or other lesions on the sole of the foot which impede the patient's ability to 
ambulate or which meet any of the aforementioned criteria. 
If the aforementioned signs and symptoms are not present, further treatment would 
! be considered medically unnecessary in nature and, therefore, not reimbursable by Medi-
1 care. 
Destruction of benign or premalignant lesions that exceed utilization parameters as 
determined by our analysis of frequency data for beneficiaries may be reviewed for medi-
cal necessity on a prepayment basis. 
Comments (con't) 
Documentation Requirements: 
If the patient presents with multiple actinic keratoses, the self-administration of topical 
2% to 5% fluorouracil cream or solution for a period of no less than two weeks and unre-
sponsiveness to the medication after two months should be documented. If the patient has 
a condition in which fluorouracil is contraindicated such as pregnancy or actinic keratosis 
(es) around the eyes on the nose, on the mouth, or on mucous membranes, the physician's 
office/progress note should reflect this. The location of the lesion(s) should be docu-
mented as well. 
If the patient presents with an actinic keratosis(es) and its appearance has changed, i.e. 
size, erythema, thickening, ulceration, and/or erosion in the tumor or tumor margins m if 
the patient has developed pain within the lesion, this should be clearly documented in the 
physician's progress/office note to substantiate removal of the lesion. 
If the patient presents with an actinic cheilitis (actinic keratosis of the lower lip) or an 
actinic keratosis on the car or conjunctiva, the exact location and a description of the le-
sion's appearance should be documented in the physician's progress/office note. 
If the patient presents with an actinic keratosis and has a history of chronic irnrnuno-
suppression; treatment of psoriasis with PUV A therapy; xcrodcrma pigmentosum, disco id 
lupus erythematosus or albinism; and/or a previous treatment of a biopsy-proven SCC, this 
should clearly be documented in the physician's progress/office note. The approximate 
starting date and duration of radiation therapy or PUV A therapy should be documented, if 
applicable. In addition, the date of organ transplantation should be documented, if applica-
ble. Any other immunosuppressive disorder should be documented with the date or ap-
proximate date of diagnosis. 
Also, if the patient has had a previous biopsy-proven SCC or other skin malignancy, 
the location of that lesion, the date of removal, and a pathology report for the previous le-
sion, if available, should be documented. In addition, for the aforementioned condi-
tions/treatments, the exact location and a description of the lesion should be documented. 
For cicatrix keratoses, the location of the scar, the type of the scar, the approximate 
date the scar developed, and a description of the size, location and appearance of the lesion 
should be documented in the physicians' progress/office note. 
Although not required at this time, a photograph of the lesion with an indication of the 
size and location would be an excellent documentation 'tool for the size, location, and ap-
pearance of the lesion. If the physician is not able to take a photograph or make a sketch 
in his/her notes regarding size, location, and appearance of the lesion, a very clear descrip-
tion of the lesion must be included in the progress/office note. 
For those benign lesions that are located in areas which subject the lesion to con-
stant irritation and/or trauma and need to be removed because of constant or frequent 
traumatization, the exact location and size of the lesion and type of irritation and/or trauma 
should be documented in the physician's progress note/office note. 
In addition, to the above, the method of destruction or removal should be de-
scribed in the physician's progress/office note for any type oflesion destroyed or re-
moved. 
_______________ __J .___ _____________ _, 
October 1996 9 
( 
( 
c- ... · 
CLARIFICATION OF MEDICAL POLICY 
FOR SKIN LESION REMOVAL 
The purpose of this communication is to clarify the reference to 
Efudex topical cream contained in our local medical review policy 
(LMRP) for skin lesion removal. This policy was published in the 
October, 1996 special edition of the "Medicare B Update!" 
The above referenced policy in no way circumvents physician 
judgment. The skin lesion LMRP simply seeks to articulate when 
excision or destruction (e.g., laser treatment, chemical treatments} is 
considered medically necessary. There are clinical criteria cited in the 
skin lesion LMRP that constitute appropriateness. Several of the 
criteria are: 
• When the patient presents with an actinic keratosis that has 
changed in size, has developed erythema, has thickened, has 
ulcerated, has ernded, has developed changes at the tumor 
margins, has become markedly hyperkeratotic, in which pain has 
developed and/or a cutaneous horn has developed; 
• When the patient presents with an actinic keratosis of the 
lower-lip, upper-lip, conjunctivae, nose, ear, or eyelid; 
• When the patient presents with actinic keratosis and has a 
history of one of the following: chronic immunosuppression, 
treatment of psoriasis with psoralen-ultrayiolet A (PUVA)" 
therapy, xeroderma pigmentosum, albinism, or· discoid lupus 
erythematosus, and/or previous treatment of a biopsy-proven 
Squamous Cell Carcinoma or other skin malignancy; 
• When a patient presents with a keratosis and has a history of 
significant exposure to therapeutic or occupational radiation 
therapy; 
• When the patient has multiple actinic keratoses and has self-
administered 2% to 5% Efudex topical cream for two to four 
weeks and the actinic keratoses have not responded to this 
treatment one to two months following treatment. 
( 
There has been considerable misunderstanding of the reference to 
Efudex. A fundamental principal in the policy is that treatment of 
asymptomatic actinic keratosis is medically unnecessary. This would 
be true for any method of treatment, e.g., surgical, laser or cryogenic 
destruction, or use of topical creams. (chemical destruction). Because 
literature indicates that lesions failing topical treatment with Efudex 
suggests a higher likelihood of malignancy, we have allcwed · for 
coverage in these cases. In other words, a failure of Efudex 
establishes a clinical criterion for a lesion being suspicious versus 
asymptomatic. 
In short, our skin lesion LMRP lays out the criteria for when the 
removal of skin lesions is appropriate. The policy both reduces 
inappropriate billing and protects beneficiaries from unnecessary 
procedures. Should additional medical literature or other information 
relevant to this matter become available, providers are always free to 
contact us and request policy changes. In addition, we continue to 
offer formal appeal rights to providers who believe their claims were 
improperly denied. 
Susan B. Towler 
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